ArticleJournal of diabetes and metabolic disorders2025
Safety and effectiveness of remdesivir in COVID-19 patients with liver dysfunction: a retrospective cohort study.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the safety and effectiveness of remdesivir in hospitalized COVID-19 patients with liver dysfunction. Methods: A retrospective cohort study analyzed medical records of 268 patients hospitalized between 2019 and 2022 with COVID-19 and elevated liver enzymes (AST and ALT). Patients were divided into remdesivir ( Results: A total of 268 patients (134 receiving remdesivir and 134 controls) were included. The remdesivir group was older, had lower oxygen saturation, and presented with more severe disease at baseline. Despite these differences, remdesivir use was associated with a significantly faster clinical recovery (adjusted β = - 2.18 days; 95% CI: - 4.206 to - 0.154; Conclusion: Remdesivir appears safe in COVID-19 patients with liver dysfunction and significantly shortens time to clinical improvement without increasing mortality or serious adverse events. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01758-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.